<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730312</url>
  </required_header>
  <id_info>
    <org_study_id>XmAb14045-01</org_study_id>
    <nct_id>NCT02730312</nct_id>
  </id_info>
  <brief_title>PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xencor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiltern International Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xencor, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of weekly intravenous
      (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after
      the first dose, and then to determine the MTD after second and subsequent infusions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as determined by the number of participants with treatment-related adverse events</measure>
    <time_frame>Baseline Day 1 through Day 56</time_frame>
    <description>Treatment-related adverse events as assessed by CTCAE v4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb14045 dosing</measure>
    <time_frame>Baseline Day 1 through Day 56</time_frame>
    <description>Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb14045 dosing</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <condition>Chronic Myeloid Leukemia, Blast Crisis</condition>
  <arm_group>
    <arm_group_label>XmAb14045</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XmAb14045</intervention_name>
    <description>Administered IV weekly up to 8 weeks, with or without induction dosing</description>
    <arm_group_label>XmAb14045</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of 1 of the following diseases:

               -  Primary or secondary AML (including erythroleukemia and eosinophilic leukemia,
                  but excluding acute promyelocytic leukemia)

               -  B-cell ALL

               -  BPDCN

               -  CML in blast phase, resistant or intolerant to tyrosine kinase inhibitor therapy

          -  Patients with relapsed or refractory disease with no available standard therapy

          -  ECOG performance status 0-2

          -  Not a candidate for, or refusing treatment with hematopoietic stem cell
             transplantation

          -  Fertile patients must agree to use effective contraception during and for 4 weeks
             after completion of study

          -  Able and willing to complete the entire study

        Exclusion Criteria:

          -  Systemic antineoplastic therapy (including cytotoxic chemotherapy and toxin
             immunoconjugates, but excluding hydroxyurea), unconjugated antibody therapy, or
             radiotherapy within 2 weeks of the first dose of study treatment, or small molecule
             kinase inhibitors within 6 elimination half-lives of the first dose of study
             treatment.

          -  Prior therapy with CD123- or IL-3R-directed immunotherapies, including monospecific
             and bsAbs, immunoconjugates, or chimeric antigen receptor- modified T-cell therapy

          -  Failure to recover from Grade 3 or 4 toxicity from previous treatment (unrelated to
             malignant bone marrow involvement)

          -  Known uncontrolled central nervous system involvement by malignant disease

          -  Absolute blast count ≥10,000/mm3 or symptoms of leukostasis

          -  Diagnosis of promyelocytic leukemia

          -  Aspartate aminotransferase or alanine aminotransferase at screening &gt;3.0 x upper limit
             of normal (ULN) unless considered due to leukemic organ involvement

          -  Bilirubin &gt;1.5 x ULN, unless prior diagnosis and documentation of leukemic organ
             involvement, ongoing hemolysis, or Gilbert's syndrome

          -  Serum creatinine &gt;2.0 x ULN, or estimated creatinine clearance &lt;40mL/min

          -  History or evidence of a clinically unstable/uncontrollable disorder, condition or
             disease other than primary malignancy, that in the opinion of the Investigator would
             pose a risk to the patient safety or interfere with the study evaluation

          -  Evidence of any active, uncontrolled bacterial, viral, parasitic fungal infections
             within 1 week of first dose of study drug

          -  Positive test for human immunodeficiency virus (HIV) -I or -II antibodies, hepatitis B
             surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV)
             antibody (unless HCV viral load test by PCR is negative). HBcAb positivity will be
             allowed if one or more of the following is true: a) HBsAb is present; b) hepatitis B
             DNA testing is negative and the patient is receiving hepatitis B reactivation
             prophylaxis with entecavir, tenofovir, or lamivudine

          -  Patient is pregnant or breast feeding, or planning to become pregnant while enrolled
             in the study, up to the End of Study visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Saville, MD</last_name>
    <role>Study Director</role>
    <affiliation>VP, Oncology Clinical Development, Xencor, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wayne Saville, MD</last_name>
    <phone>858-633-6632</phone>
    <email>wsaville@xencor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chelsea Johnson, RN</last_name>
    <phone>858-480-3891</phone>
    <email>cjohnson@xencor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Fairchild, RN</last_name>
      <email>Fairchild.carol@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Brown</last_name>
      <phone>404-851-8238</phone>
      <email>Stacey.brown@northside.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Stock, MD</last_name>
      <email>wstock@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristy Johnson</last_name>
      <phone>773-702-4936</phone>
      <email>kjohnson@medicine.bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasturi Ganesh Barki</last_name>
      <phone>614-685-6227</phone>
      <email>kasturi.ganesh@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhad Ravandi-Kashani, MD</last_name>
      <phone>713-745-0394</phone>
      <email>fravandi@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raya Mawad, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tenzin Tsomo</last_name>
      <phone>206-386-2831</phone>
      <email>Tenzin.Tsomo@swedish.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>B-ALL</keyword>
  <keyword>BPDCN</keyword>
  <keyword>CML</keyword>
  <keyword>Blast Crisis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

